An observational study in Duchene Muscular Dystrophy and Becker Muscular Dystrophy, sponsored by Nantes University Hospital. Recruiting at 1 site in France. Open to male participants aged 5 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by Nantes University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Muscular Dystrophy, Duchenne with a site in France — 11 open to participants now, 13 under way, 4 of them phase 3. Muscular Dystrophy, Duchenne · France.
Among the 66 studies in Muscular Dystrophy, Duchenne with a site in France, this one is the 12th largest by planned enrollment of the 15 observational ones that give a count, is one of 5 that started in 2026, is one of 15 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 62nd registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →11 of the 66 studies in Muscular Dystrophy, Duchenne with a site in France are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in France, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
University Hospital, Clermont-Ferrand · Sites in France
Ages 2+ · Healthy volunteers
Assistance Publique Hopitaux De Marseille · Sites in France
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Women only
Italfarmaco · Sites in France, Belgium, Canada and 9 more countries
Ages 9–17 · Men only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 5 Years to 60 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 16 · Phase 3 24
First in 2006; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 132 observational studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 83 across the 50 interventional studies, 220 across the 15 observational. Of the 46 that completed or were terminated, 18 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 66 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Nantes University Hospital has 1 study filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
2 of the studies in Muscular Dystrophy, Duchenne with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06833489Assistance Publique Hopitaux De MarseilleTranscriptomic Analysis to Put an End to Misdiagnosis in Patients With Rare Muscle Diseases | 2026-12-01 |
| NCT06147414Assistance Publique - Hôpitaux de ParisDevelopment of Non-Invasive Prenatal Diagnosis for Single Gene Disorders | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies in Muscular Dystrophy, Duchenne with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to determine the potential of a multiparametric ultrasound approach to non-invasively monitor disease progression and to serve as an objective outcome measure for future clinical trials in Duchenne and Becker Muscular Dystrophies.
The investigators will compare the muscles of ambulatory or non-ambulatory boys/men with Duchenne and Becker Dystrophies with muscles of healthy age-matched individuals of the same age and monitor disease progression in those with muscular dystrophies over a 12-month year period.
The ultrafast ultrasound technology used in this study allows the simultaneous assessment of muscle structure, mechanics and physiology, including stiffness, anisotropy, viscosity, intramuscular fat, muscle volume, and microvascular perfusion. The amount of muscle alteration measured will be related to performance in daily activities, such as walking and muscle strength, in order to identify sensitive and objective markers of disease progression.
Duchenne and Becker muscular dystrophies (DMD/BMD) are the most common forms of muscular dystrophies, progressive muscle wasting diseases leading to weakness and devastating functional impairment. DMD is characterized by predominant involvement in skeletal, including respiratory, and cardiac muscles. Diagnosis is usually established at three to four years of age. Patients typically show muscle degeneration that worsens with age, leading to wheelchair dependency usually by the age of ten, assisted ventilation before the age of twenty, and premature death in the second to fourth decade. BMD shows a similar clinical phenotype but a later onset (approximately twelve years of age), a slower disease progression, delayed or no loss of ambulation, and variable involvement of the cardiac and respiratory systems. Considerable heterogeneity has been observed within and across the DMD/BMD phenotypes, which makes the design and analysis of clinical trials and prediction of the disease progression challenging.
Recent inconsistent results in DMD clinical development programs have also raised questions about the validity of the methods used to evaluate treatment efficacy. The number of potentially effective therapeutic approaches for DMD/BMD has rapidly increased over recent years, and thus the demand for validated outcome measures to demonstrate clinically meaningful therapeutic response over time in clinical trials (e.g., one year) is higher than ever. Regulatory agencies (e.g., FDA) have explicitly been encouraging the development of imaging biomarkers that may serve as surrogate markers of how patients will respond to investigational treatments in DMD/BMD.
This study aims to validate the potential of innovative ultrasound imaging methods, developed by our research consortium over recent years, as imaging tools to monitor disease progression and serve as a surrogate outcome measure for clinical trials in muscular dystrophies. Using cutting-edge ultrasound imaging techniques, including shear wave elastography, matrix approach, 3D freehand ultrasound, and power Doppler we will quantify much needed surrogate measures of muscle damage and progressive degeneration such as intramuscular fat content, fibrosis, muscle apoptosis and structural disorganization, inflammation, hypertrophy/atrophy, and intramuscular blood flow, in the lower and upper extremity muscles. An easy-to-apply multiparametric approach will be developed to assess the most important hallmarks of muscle degeneration associated with the most common and devastating muscular dystrophies.
Study Population
This bicentric study will include 60 participants:
18 male patients with Duchenne Muscular Dystrophy (DMD), aged 5 to 30 years (ambulant and non-ambulant),
18 male patients with Becker Muscular Dystrophy (BMD), aged 5 to 60 years,
and 24 healthy male subjects, aged 5 to 60 years, without neuromuscular disease or limb injury.
All participants must have French social insurance coverage and provide informed consent (from parents or legal representatives for minors).
Patients will be recruited mainly from the CHU de Nantes, the Institut de Myologie (Paris), and through the French Muscular Dystrophy Association (AFM-Téléthon). Healthy volunteers will be recruited from Nantes University staff, students, and their children.
The inclusion of minors is necessary because Duchenne and Becker muscular dystrophies are X-linked genetic disorders diagnosed in childhood, and disease severity increases with age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Inability to undergo static exam, missing measurement site (resection/amputation), neurocognitive impairment preventing
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Age matched non-affected men, matched for men with Becker and Duchenne Muscular Dystrophies
This group will include ambulatory and non-ambulatory boys/men with Duchenne Muscular Dystrophy ranging from 5-30 years old.
This group will include ambulatory and non-ambulatory men with Becker Muscular Dystrophy ranging from 5-60 years old.
Baseline mechanical, structural, and physiological muscle ultrasound parameters
Assessment of muscle stiffness (kPa) in the lower extremity and/or upper extremity muscles across three participant groups
Time frame: Baseline
Baseline mechanical, structural, and physiological muscle ultrasound parameters
Assessment of anisotropy (a.u.) in the lower extremity and/or upper extremity muscles across three participant groups
Time frame: Baseline
Baseline mechanical, structural, and physiological muscle ultrasound parameters
Assessment of viscosity (Np/mm) in the lower extremity and/or upper extremity muscles across three participant groups
Time frame: Baseline
Baseline mechanical, structural, and physiological muscle ultrasound parameters
Assessment of nonlinear elastic parameters (kPa) in the lower extremity and/or upper extremity muscles across three participant groups
Time frame: Baseline
Baseline mechanical, structural, and physiological muscle ultrasound parameters
Assessment of intramuscular fat (m/s) in the lower extremity and/or upper extremity muscles across three participant groups
Time frame: Baseline
Baseline mechanical, structural, and physiological muscle ultrasound parameters
Assessment of intramuscular blood flow (%) in the lower extremity and/or upper extremity muscles across three participant groups
Time frame: Baseline
Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters
Assessment of muscle stiffness (kPa) in the lower extremity and/or upper extremity muscles across three participant groups
Time frame: 12 months
Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters
Assessment of anisotropy (a.u.) in the lower extremity and/or upper extremity muscles across three participant groups
Time frame: 12 months
Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters
Assessment of viscosity (Np/mm) in the lower extremity and/or upper extremity muscles across three participant groups
Time frame: 12 months
Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters
Assessment of nonlinear elastic parameters (kPa) in the lower extremity and/or upper extremity muscles across three participant groups
Time frame: 12 months
Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters
Assessment of intramuscular fat (m/s) in the lower extremity and/or upper extremity muscles across three participant groups
Time frame: 12 months
Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters
Assessment of intramuscular blood flow (%) in the lower extremity and/or upper extremity muscles across three participant groups
Time frame: 12 months
Muscle function
Muscle strength will be evaluated by dynamometry
Time frame: Baseline and changes from baseline in at 12 months
Functional outcomes
10-Meter Walk Test in DMD and BMD participants
Time frame: Baseline and changes from baseline at 12 months
Functional outcomes
NorthStar Ambulatory Assessment performance in DMD and BMD participants
Time frame: Baseline and changes from baseline at 12 months
Correlations between ultrasound measures, muscle function and functional outcomes
In both BMD and DMD, the correlation between each ultrasound imaging parameter \[muscle stiffness (kPa), anisotropy (a.u.), viscosity (Np/mm), nonlinear elastic parameters (kPa), intramuscular fat (m/s), muscle volume (ml), and intramuscular blood flow (%)\] and all functional endpoints \[NorthStar Ambulatory Assessment, 10-Meter Walk Test\] will be determined, as well as the ability of ultrasound measures to predict future change and loss in function.
Time frame: Through study completion, 12 months
Started Mar 2026 (actual). Primary completion is estimated for Mar 2029, 36 months after the start.
Of 52 non-industry observational studies under Muscular Dystrophy, Duchenne, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 120. This study's planned 36 months is close to that.
Counting every sponsor, half of 63 studies reached it within 40 months; a quarter within 12 and three quarters within 120.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →